Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NURO

NURO - NeuroMetrix Inc Stock Price, Fair Value and News

$4.58 
Market Closed

Price Targets

NURO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NURO Price Action

Last 30 days

5.8%

Last 90 days

4.8%

Trailing 12 Months

3.9%

NURO RSI Chart

NURO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NURO Valuation

Market Cap

9.4M

Price/Earnings (Trailing)

-1.21

Price/Sales (Trailing)

3.11

EV/EBITDA

-0.75

Price/Free Cashflow

-1.32

NURO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

NURO Fundamentals

NURO Revenue

NURO Earnings

NURO Profitability

Free Cashflow Yield

-75.57%

NURO Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20245.3M4.4M3.8M3.0M
20237.7M7.2M6.4M5.9M
20228.4M8.3M8.2M8.3M
20217.4M8.2M8.2M8.3M
20206.5M6.5M6.5M7.4M
201917.0M14.6M13.0M10.1M
201817.5M17.0M17.1M16.0M
201714.1M15.7M15.9M17.1M
20168.3M9.7M11.0M12.0M
20155.5M5.3M6.0M7.3M
20145.2M5.4M5.5M5.5M
20136.9M5.8M5.4M5.3M
20129.6M9.2M8.4M7.6M
201113.2M12.0M11.1M10.4M
2010022.1M18.0M13.9M
200900026.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About NeuroMetrix Inc

NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
 CEO
 WEBSITEneurometrix.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES27

NeuroMetrix Inc Frequently Asked Questions

NURO is the stock ticker symbol of NeuroMetrix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri May 09 2025, market cap of NeuroMetrix Inc is 9.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NURO's fair value in chart for subscribers.

The fair value guage provides a quick view whether NURO is over valued or under valued. Whether NeuroMetrix Inc is cheap or expensive depends on the assumptions which impact NeuroMetrix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NURO.

As of Fri May 09 2025, NURO's PE ratio (Price to Earnings) is -1.21 and Price to Sales (PS) ratio is 3.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NURO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, NeuroMetrix Inc has provided -0.478 (multiply by 100 for percentage) rate of return.